表紙
市場調査レポート

Botox(片頭痛)- 予測と市場分析

Botox (Migraine) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 301153
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
Botox(片頭痛)- 予測と市場分析 Botox (Migraine) - Forecast and Market Analysis to 2023
出版日: 2014年03月31日 ページ情報: 英文 42 Pages
概要

片頭痛の治療薬市場は、ジェネリック医薬品で飽和状態で、上市されている残りのブランド薬は、慢性片頭痛の治療薬Botoxを除き、今後数年間で独占性を失うと見られています。片頭痛の治療薬市場は、2023年までに37億米ドル規模まで拡大し、CAGRで3.6%の成長が予測されています。

当レポートでは、片頭痛の治療薬であるBotoxについて調査分析し、疾病の概要と治療ガイドライン、競合情勢、製品情報、売上予測などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
    • 予後
  • 症状
    • 前兆
    • 前駆症状
    • 頭痛
    • 後発症状

第4章 疾病の管理

  • 治療の概要
    • 急性片頭痛
    • 予防的片頭痛

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価

第6章 Botox(onabotulinum toxin A)

  • 概要
  • 効能
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表

目次
Product Code: GDHC378DFR

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Onabotulinum toxins are produced by the bacterium Clostridium botulinum, which was first isolated in 1895. They are potent inhibitors of neurotransmission between neurons themselves and also to muscle. Out of the seven subtypes of onabotulinum toxin (A-G), onabotulinum neurotoxin type A is the most commonly used and thoroughly investigated subtype. Onabotulinum toxin type A is currently marketed as Botox by Allergan. In recent years, Botox has gained a great deal of attention and has gained FDA (2010) as well as MHRA (2013) approval as treatment for chronic migraine.

Scope

  • Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Botox including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Botox for the top five countries from 2012 to 2023.
  • Sales information covered for the US, Germany, Italy, Spain and the UK.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Migraine
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Botox performance
  • Obtain sales forecast for Botox from 2012-2023 in the top five countries (the US, Germany, Italy, Spain and the UK)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
  • 3.2. Symptoms
    • 3.2.1. Premonitory Phase
    • 3.2.2. Aura Phase
    • 3.2.3. Headache Phase
    • 3.2.4. Postdrome Phase

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Acute Migraine Treatment
    • 4.1.2. Preventive Migraine Treatment

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Botox (onabotulinum toxin A)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Migraine Patients
    • 7.4.2. Percent Drug-treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. Survey of Prescribing Physicians
  • 7.7. About the Authors
    • 7.7.1. Author
    • 7.7.2. Reviewer
    • 7.7.3. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Classification of Migraine Subtypes
  • Table 2: Diagnostic Criteria for Migraine with Aura
  • Table 3: Diagnostic Criteria for Migraine without Aura
  • Table 4: Treatment Guidelines for Migraine
  • Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013
  • Table 6: Product Profile - Botox
  • Table 7: Botox SWOT Analysis, 2013
  • Table 8: Global Sales Forecasts ($m) for Botox, 2012-2023
  • Table 9: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Migraine Treatment Algorithm in the 7MM
Back to Top